Format

Send to

Choose Destination
See comment in PubMed Commons below
Chem Biol Interact. 2005 May 30;153-154:223-9.

Do children have increased susceptibility for developing secondary acute myelogenous leukemia?

Author information

1
University of Colorado Health Sciences Center, Molecular Toxicology and Environmental Health Sciences, 4200 East 9th Avenue, Denver, CO 80262, USA. dpyatt@summittoxicology.com

Erratum in

  • Chem Biol Interact. 2005 Aug 15;155(3):191.

Abstract

This study was undertaken to evaluate the effects of age on a child's susceptibility to developing leukemia following exposure to known leukemogenic agents. The clinical literature describing the risk of developing acute myelogenous leukemia (AML) following treatment with alkylating agents or topoisomerase reactive drugs (known leukemogens) was used as a basis for this investigation. Based on this preliminary assessment, the age of the child does not appear to be an independent variable for risk following treatment with either class of drug. Although the number of studies and cases was very small, the available scientific and medical literature does not support the hypothesis that children will necessarily have an altered susceptibility or increased risk of developing chemotherapy-induced AML.

PMID:
15878160
DOI:
10.1016/j.cbi.2005.03.026
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center